Business
Cipher introduces Epuris(TM) (isotretinoin) capsules in Canadian market
Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, July 2, 2013 /CNW/ - At the 8...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\nToronto Stock Exchange Symbol: DND\n\n\nMISSISSAUGA, ON, July 2, 2013 /CNW/ - At the 88th annual Canadian Dermatology Association Conference held in Quebec City\n over the July 1st weekend, Cipher Pharmaceuticals Inc. (TSX: DND) (\"Cipher\") announced\n the Canadian launch of Epuris™, a novel brand formulation of the acne medication isotretinoin for the\n treatment of severe acne in patients aged 12 years or older.\n\n\nThe Canadian Dermatology Association estimates that acne affects nearly\n 20%, or 5.6 million, Canadians and that more than 80% of acne sufferers\n are between the ages of 12 and 24. According to IMS Health, Canadian\n isotretinoin sales reached $15 million in 2012.\n\n\n\"We are pleased to announce the launch of Epuris, a valuable new\n treatment option for Canadian dermatologists and their patients who\n suffer from severe acne,\" said Larry Andrews, CEO of Cipher. \"This\n represents an important milestone on the path to building Cipher's\n commercial portfolio and franchise in Canada. We expect this will be\n the first of a number of products we introduce, beginning in\n Dermatology and, over time, in other specialty markets.\"\n\n\nAbout Epuris™\n\n\nEpuris (isotretinoin) is a treatment for severe acne with the\n well-established clinical benefits physicians know and the reliable\n absorption and flexible dosing that both patients and physicians need.\n While bioequivalent to Accutane® under high fat fed conditions Epuris\n provides 83% greater absorption under fasted conditions.1  It is available in 10mg, 20mg, 30mg, and 40mg oral capsules for\n flexible, individualized dosing according to the patients weight and\n disease severity.1\n\nFor more information, please visit www.epuris.ca for the full product monograph and for important information about\n indications, contraindications, warnings and precautions.\n\n\nAbout Cipher Pharmaceuticals Inc.\n\n\nCipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty\n pharmaceutical company with three commercial products and a fourth in\n development. Our product candidates are typically improved formulations\n of successful, currently marketed drugs. We in-license a product,\n manage the required clinical development and regulatory approval\n process, and either out-license it to a marketing partner, or, in\n Canada, ...